NCT01026285

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Observational, Non-interventional Registry to Assess Medication Usage Patterns in Clinical Routine Practice, in Subjects Receiving Antipsychotic Treatment With Risperidone Long Acting Injectable (Gluteal or Deltoid) or Oral Antipsychotics

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,085 (actual)
• Sponsor: Janssen-Cilag International NV · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

International Observational Registry on Schizophrenia

Detailed description

This is an observational, non-interventional registry designed to assess medication usage patterns and to explore, in clinical routine practice, long-term outcomes and relevant factors for patient adherence to treatment, in patients receiving antipsychotic treatment with risperidone long-acting injectable (RLAI) or oral antipsychotics. Six month retrospective data and 1 year prospective data will be collected. According to label

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Risperidone Long-Acting injectable or oral antipsychotics	According to label

Timeline

• Start date: 2009-06-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2009-12-04
• Last updated: 2013-06-24

Locations

98 sites across 8 countries: Czechia, France, Germany, Greece, Russia, South Africa, Spain, Turkey (Türkiye)